STOCK TITAN

Quince Therapeutics, Inc. - QNCX STOCK NEWS

Welcome to our dedicated news page for Quince Therapeutics (Ticker: QNCX), a resource for investors and traders seeking the latest updates and insights on Quince Therapeutics .

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Quince Therapeutics 's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Quince Therapeutics 's position in the market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.84%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.11%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
management
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.8%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.69%
Tags
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
71.02%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
33.66%
Tags
none
Quince Therapeutics, Inc.

Nasdaq:QNCX

QNCX Rankings

QNCX Stock Data

42.93M
27.05M
17.06%
28.16%
4.3%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
United States of America
SOUTH SAN FRANCISCO

About QNCX

cortexyme is developing therapeutics based on data supporting a new theory of the cause of alzheimer's and other degenerative disorders. cortexyme is targeting a specific, undisclosed pathogen tied to neurodegeneration and beta amyloid production. the target has been validated in a number of animal models and cortexyme is currently moving a proprietary small molecule towards human clinical testing.